Thermo Fisher Scientific filings document operating results, material agreements, governance matters and capital-structure disclosures for a global supplier of scientific instruments, laboratory products, diagnostics, life science tools and pharmaceutical services. Recent Form 8-K reports include quarterly and annual results, acquisition-related events and definitive agreements.
The company’s proxy materials cover shareholder voting and board-governance matters. Its securities disclosures identify common stock and multiple NYSE-listed senior note classes, while Form 25 filings document removal from listing and registration for specific senior notes. The filing record also includes risk-factor and corporate disclosure categories tied to Thermo Fisher’s operating businesses and financing structure.
Thermo Fisher Scientific (TMO) – Form 4 insider activity
Chairman & CEO Marc N. Casper exercised 18,000 previously vested employee stock options at a $253.99 strike price on 6–7 Aug 2025 and immediately sold the same number of shares under a pre-arranged Rule 10b5-1 plan. Weighted-average sale prices ranged from $446.92 to $456.41, implying gross proceeds of roughly $8.4 million and an intrinsic gain of about $3.6 million versus the $4.6 million exercise cost. These trades are coded “M/S,” indicating routine option exercise and sale.
After the transactions, Casper’s direct stake remains essentially unchanged at 115,173 common shares (≈$52 million at the sale prices). He also reports indirect ownership of 30,908 shares through family trusts and a private entity. Option holdings declined to 35,250 shares expiring 26 Feb 2026.
- No impact on Thermo Fisher’s cash; shares came from option conversion.
- Continued large equity position suggests ongoing alignment, although repeated same-day sales could be viewed as mild insider-selling pressure.
Thermo Fisher Scientific (TMO) – Form 144 filing. An insider, identified in the filing’s past-sales table as Marc N. Casper, has given notice of intent to sell up to 8,000 common shares through Fidelity Brokerage on the NYSE.
The shares have an aggregate market value of $3.64 million (≈$455 per share). With 377.6 million shares outstanding, the proposed sale equals roughly 0.002 % of the float, signalling an immaterial ownership impact and no dilution.
The insider also reported a recent sale of 10,000 shares on 08-06-2025 for $4.52 million. Form 144 is a pre-trade notice; execution is not guaranteed, and the filer attests to possessing no undisclosed adverse information. The document contains no operational, earnings or strategic updates.
Thermo Fisher Scientific’s Q2-25 results show modest growth, lower margins and weaker cash conversion.
Total revenue rose 3% YoY to $10.86 b; product sales +1%, services +5%. Operating income edged up 1% to $1.83 b but margin slipped 40 bp to 16.9% after $82 m of restructuring charges. Net income attributable to TMO increased 4.5% to $1.62 b; diluted EPS climbed 6% to $4.28.
For six months, revenue reached $21.22 b (+1.6%) and EPS $8.26 (+10%). Operating cash flow fell 34% to $2.12 b as inventories (+12%) and receivables (+5%) expanded. The company repurchased $2.0 b of shares, paid $311 m in dividends and issued $2.84 b of new debt, lifting total borrowings to $35.3 b (par) while cash rose to $4.58 b.
Segment revenue YoY: Life Sciences Solutions +6% ($2.50 b); Analytical Instruments −3% ($1.73 b); Specialty Diagnostics +1% ($1.13 b); Laboratory Products & Biopharma Services +4% ($6.00 b). Growth came from North America (+3%) and Europe (+6%); Asia-Pacific declined 3%.
The effective tax rate dropped to 5.6% YTD (vs 12.2%) thanks to a $153 m deferred-tax benefit on intra-entity transfers. Management expects another ~$140 m of restructuring, mainly in Laboratory Products.
Investor focus: steady EPS aided by tax gains, soft operating margin, cash-flow pressure, and higher leverage partially offset by strong liquidity.
Thermo Fisher Scientific (TMO) — Form 4 insider transaction
Executive Vice President Gianluca Pettiti reported the sale of 400 common shares on 07/25/2025 at $479.98 per share, generating roughly $0.19 million in proceeds. The trade was executed under a Rule 10b5-1 plan that Pettiti adopted on 02/10/2025, indicating it was pre-scheduled and not based on current market conditions.
Post-transaction, the executive directly owns 22,366.925 shares. No derivative securities were bought or sold and no indirect holdings were reported. The filing discloses no additional company fundamentals or other insider activity.
- Transaction size is modest relative to Pettiti’s remaining stake, suggesting continued alignment with shareholders.
- No impact on share count or control structure; purely a personal liquidity event.
On 25 Jul 2025, Thermo Fisher Scientific, Inc. (TMO) filed a Form 144 indicating that Gianluca Pettiti intends to sell up to 400 common shares through Fidelity Brokerage Services on the NYSE. The proposed sale, valued at $191,992, equals roughly 0.0001 % of the 377,493,912 shares outstanding, implying negligible dilution or market impact.
The stock to be sold stems from two restricted-stock vestings received as compensation (235 shares on 23 Aug 2024 and 165 shares on 28 Aug 2024). Pettiti has already sold 700 shares over the past three months, generating gross proceeds of $293,423.
No Rule 10b5-1 trading-plan date is disclosed. The filer certifies possession of no undisclosed adverse information, and the notice contains no financial results, guidance, or operational updates. Overall, the filing reflects a routine, small-scale insider transaction with limited investment significance.